Product Description
Mechanisms of Action: PLA2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Acute Coronary Syndrome|Atherosclerosis|Coronary Disease|Coronary Artery Disease|Myocardial Ischemia
Phase 2: Atherosclerosis|Diabetic Retinopathy|Myocardial Ischemia|Coronary Artery Disease|Macular Edema|Dyslipidemia
Phase 1: Kidney Diseases|Atherosclerosis|Asthma|Blister|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
5R01HL092954 | P3 |
Completed |
Atherosclerosis |
2015-11-01 |
|
NCT02058641 | P1 |
Completed |
Type 2 Diabetes|Blister|Atherosclerosis |
2014-08-18 |
|
JapicCTI-101024 | P3 |
Completed |
Acute Coronary Syndrome |
2014-04-30 |
|
SOLID-TIMI 52 | P3 |
Completed |
Acute Coronary Syndrome |
2014-04-01 |